AU2016211671B2 - Methods and compositions for inducing hematopoietic cell differentiation - Google Patents

Methods and compositions for inducing hematopoietic cell differentiation Download PDF

Info

Publication number
AU2016211671B2
AU2016211671B2 AU2016211671A AU2016211671A AU2016211671B2 AU 2016211671 B2 AU2016211671 B2 AU 2016211671B2 AU 2016211671 A AU2016211671 A AU 2016211671A AU 2016211671 A AU2016211671 A AU 2016211671A AU 2016211671 B2 AU2016211671 B2 AU 2016211671B2
Authority
AU
Australia
Prior art keywords
cells
pluripotent stem
cell
derived
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016211671A
Other languages
English (en)
Other versions
AU2016211671A1 (en
Inventor
Raedun CLARKE
Bahram Valamehr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fate Therapeutics Inc
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of AU2016211671A1 publication Critical patent/AU2016211671A1/en
Priority to AU2022203153A priority Critical patent/AU2022203153B2/en
Application granted granted Critical
Publication of AU2016211671B2 publication Critical patent/AU2016211671B2/en
Priority to AU2024287257A priority patent/AU2024287257A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2311—Interleukin-11 (IL-11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1369—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2016211671A 2015-01-26 2016-01-26 Methods and compositions for inducing hematopoietic cell differentiation Active AU2016211671B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022203153A AU2022203153B2 (en) 2015-01-26 2022-05-11 Methods and compositions for inducing hematopoietic cell differentiation
AU2024287257A AU2024287257A1 (en) 2015-01-26 2024-12-30 Methods and compositions for inducing hematopoietic cell differentiation

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562107517P 2015-01-26 2015-01-26
US62/107,517 2015-01-26
US201562251016P 2015-11-04 2015-11-04
US62/251,016 2015-11-04
PCT/US2016/014918 WO2016123100A1 (en) 2015-01-26 2016-01-26 Methods and compositions for inducing hematopoietic cell differentiation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022203153A Division AU2022203153B2 (en) 2015-01-26 2022-05-11 Methods and compositions for inducing hematopoietic cell differentiation

Publications (2)

Publication Number Publication Date
AU2016211671A1 AU2016211671A1 (en) 2017-08-10
AU2016211671B2 true AU2016211671B2 (en) 2022-05-26

Family

ID=56544232

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016211671A Active AU2016211671B2 (en) 2015-01-26 2016-01-26 Methods and compositions for inducing hematopoietic cell differentiation
AU2022203153A Active AU2022203153B2 (en) 2015-01-26 2022-05-11 Methods and compositions for inducing hematopoietic cell differentiation
AU2024287257A Pending AU2024287257A1 (en) 2015-01-26 2024-12-30 Methods and compositions for inducing hematopoietic cell differentiation

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022203153A Active AU2022203153B2 (en) 2015-01-26 2022-05-11 Methods and compositions for inducing hematopoietic cell differentiation
AU2024287257A Pending AU2024287257A1 (en) 2015-01-26 2024-12-30 Methods and compositions for inducing hematopoietic cell differentiation

Country Status (7)

Country Link
US (5) US10626372B1 (https=)
EP (1) EP3250680A4 (https=)
JP (5) JP6800859B2 (https=)
CN (2) CN107429230B (https=)
AU (3) AU2016211671B2 (https=)
SG (2) SG11201706041XA (https=)
WO (1) WO2016123100A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210062139A1 (en) * 2017-12-28 2021-03-04 Kaneka Corporation Cell aggregation suppressor
US20240043800A1 (en) * 2021-02-05 2024-02-08 Sungkwang Medical Foundation Method for differentiating pluripotent stem cell-derived hemogenic endothelial cells into lymphoid lineage cells

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
RU2018106515A (ru) 2015-07-21 2019-08-21 Зе Чилдрен'С Медикал Сентер Корпорейшн Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения
CN108431211B (zh) * 2015-10-20 2026-03-24 富士胶片细胞动力公司 通过遗传编程的多谱系造血前体细胞产生
JP6928604B2 (ja) 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA3010236A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3405568A4 (en) 2016-01-20 2019-12-04 Fate Therapeutics, Inc. COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
EP3510145A4 (en) 2016-09-06 2020-03-25 The Children's Medical Center Corporation IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS
WO2018106595A1 (en) 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2018147801A1 (en) * 2017-02-07 2018-08-16 Agency For Science, Technology And Research Methods and kits for generating mimetic innate immune cells from pluripotent stem cells
EP4272551A3 (en) * 2017-02-28 2024-03-06 The Regents of the University of California Differentiation and use of human microglia-like cells from pluripotent stem cells and hematopoietic progenitors
US12129487B2 (en) 2017-03-27 2024-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to obtain lymphoid progenitors
WO2018195175A1 (en) 2017-04-18 2018-10-25 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
CA3068604A1 (en) 2017-06-13 2018-12-20 Fate Therapeutics, Inc. Compositions and methods for inducing myeloid suppressive cells and use thereof
EP3654986A2 (en) 2017-07-19 2020-05-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CN107488629A (zh) * 2017-08-14 2017-12-19 中国科学院广州生物医药与健康研究院 一种人多能干细胞的定向分化方法
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
SG11202006731VA (en) * 2018-01-18 2020-08-28 Agency Science Tech & Res Method for differentiation of human pluripotent stem cell lines in suspension culture
CN108300695B (zh) * 2018-02-07 2021-08-06 清华大学 一种人类多能干细胞向造血干细胞分化的方法及培养添加剂
JP2021514185A (ja) * 2018-02-14 2021-06-10 サニーブルック リサーチ インスティチュート Ｔ細胞系列の細胞を発生させるための方法
FR3079239A1 (fr) * 2018-03-23 2019-09-27 Centre National De La Recherche Scientifique Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
US12497593B2 (en) 2018-09-07 2025-12-16 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
CN109182251A (zh) * 2018-10-08 2019-01-11 吉林大学 一种扩增内皮祖细胞数量的低血清培养基
WO2020154412A1 (en) * 2019-01-22 2020-07-30 Washington University Compositions and methods for generating hematopoietic stem cells (hscs)
CN111607566B (zh) * 2019-02-22 2023-04-14 安徽中盛溯源生物科技有限公司 从人多能干细胞分化为造血祖细胞的方法及其应用
CN111154719B (zh) * 2019-02-28 2024-03-01 西湖生物医药科技(杭州)有限公司 利用外周血体外制备成熟红细胞的方法及制剂
CN110106146B (zh) * 2019-03-28 2021-04-02 中国人民解放军军事科学院军事医学研究院 化合物富马酸酮替芬在促进干细胞因子合成和分泌中的用途
WO2020206267A1 (en) * 2019-04-03 2020-10-08 Akron Biotechnology, Llc Cryopreservation and cell culture media
EP3952891A4 (en) * 2019-04-09 2023-01-25 Rutgers, the State University of New Jersey Methods for enriching populations of cells
CN110025014A (zh) * 2019-04-18 2019-07-19 宝康士(中国)保健食品销售有限公司 混合菌株发酵制备富含益生菌和nk细胞的基底液的方法
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
GB201911957D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of producing haemogenic progenitor cells from pluripotent stem cells
AU2020333918A1 (en) * 2019-08-20 2022-03-24 Adaptimmune Limited Culture medium for haematopoietic induction
KR20220054359A (ko) * 2019-08-28 2022-05-02 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병을 치료하는 방법
CN114729317A (zh) 2019-11-29 2022-07-08 新泽西鲁特格斯州立大学 脐带血血浆制品、组织和细胞外泌体的分离方法，其组合物及使用方法
KR20220113349A (ko) * 2019-12-11 2022-08-12 리페아론 게엠베하 생물반응기의 현탁액에서 줄기세포의 확장
EP4081035A4 (en) * 2019-12-23 2024-03-27 Boston Medical Center Corporation HUMAN IPSC-BASED DERIVATION OF NK AND T CELLS USING EARLY NOTCH INDUCTION
EP4110904A1 (en) 2020-02-28 2023-01-04 Takeda Pharmaceutical Company Limited Method for producing natural killer cells from pluripotent stem cells
US20230097226A1 (en) * 2020-02-28 2023-03-30 Purdue Research Foundation Generating aorta-gonad-mesonephros-like hematopoietic cells from human pluripotent stem cells under a defined condition
EP4138893A4 (en) * 2020-04-21 2024-06-12 Intima Bioscience, Inc. CELLULAR VACCINE PLATFORM AND METHODS OF USE THEREOF
CN111808812B (zh) * 2020-08-31 2020-12-15 首都医科大学附属北京友谊医院 一种用于多能干细胞向造血干细胞分化的材料和方法
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
GB202102297D0 (en) * 2021-02-18 2021-04-07 Adaptimmune Ltd Methods of Producing Haemogenic Endothelial Cells from Pluripotent Stem Cells
AU2022229913A1 (en) * 2021-03-05 2023-09-21 The Children's Medical Center Corporation Stroma-free nk cell differentiation from human pluripotent stem cells
IL307219A (en) * 2021-03-31 2023-11-01 Garuda Therapeutics Inc Pluripotent stem cell-derived hematopoietic lineages
DE202022002866U1 (de) 2021-04-01 2024-03-20 The Regents Of The University Of California Genetische Modifikation von Säugetierzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten
CN113215086A (zh) * 2021-05-26 2021-08-06 杭州原生生物科技有限公司 一种多能干细胞诱导分化成造血干细胞的培养基及方法
MX2023014979A (es) * 2021-06-15 2024-02-09 Takeda Pharmaceuticals Co Metodo para producir linfocitos citoliticos naturales a partir de celulas madre pluripotentes.
CN117957313A (zh) * 2021-07-19 2024-04-30 修复免疫股份有限公司 从多能干细胞生产免疫细胞群的方法
KR102595504B1 (ko) * 2021-10-13 2023-10-30 랩인큐브 주식회사 줄기세포의 분화가 가능한 나노 플랫폼 및 이의 제조방법
EP4448729A1 (en) 2021-12-17 2024-10-23 Umoja Biopharma, Inc. Cytotoxic innate lymphoid cell and uses thereof
CN118829724A (zh) * 2022-01-20 2024-10-22 科济生物医药（上海）有限公司 诱导细胞分化的方法
US20250122474A1 (en) * 2022-01-31 2025-04-17 Healios K.K. Production method for natural killer cells
US20250145961A1 (en) * 2022-02-15 2025-05-08 The University Of Birmingham Generating bone marrow organoids
KR20230143112A (ko) * 2022-04-01 2023-10-11 (주) 테라베스트 유도만능줄기세포로부터 생산된 자연살해세포, 이의 제조 방법 및 이의 용도
CN114752548B (zh) * 2022-04-28 2025-01-21 澳门大学 一种诱导干细胞分化为角质细胞的方法
CN114774365B (zh) * 2022-06-16 2022-08-23 呈诺再生医学科技(北京)有限公司 一种诱导iPSC分化获得CD34+细胞和NK细胞的方法及其应用
CN114958771B (zh) * 2022-06-27 2023-12-05 广东康盾创新产业集团股份公司 一种ipsc-car-nk细胞的制备方法
EP4577641A1 (en) * 2022-08-25 2025-07-02 Trailhead Biosystems Inc. Methods and compositions for generating hemogenic endothelial cells from pluripotent stem cells
CN120239746A (zh) 2022-09-19 2025-07-01 图恩疗法股份有限公司 用于调节t细胞功能的组合物、系统和方法
WO2024175080A1 (zh) 2023-02-24 2024-08-29 士泽生物医药（苏州）有限公司 诱导干细胞分化为nk细胞的试剂盒及其应用以及nk细胞联合tmz在治疗tmz耐药型gbm中的应用
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
CN121909284A (zh) 2023-07-31 2026-04-21 图恩疗法股份有限公司 用于调节il-2基因表达的组合物和方法
WO2025125560A1 (en) * 2023-12-15 2025-06-19 Institut National de la Santé et de la Recherche Médicale Methods for generating myeloid cells
CN117757625B (zh) * 2023-12-20 2026-03-27 中国医学科学院输血研究所 基于一种多孔材料的诱导nk细胞的方法
WO2025219552A1 (en) * 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
GB202405750D0 (en) * 2024-04-24 2024-06-05 Plasticell Ltd Therapy

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
JP3626206B2 (ja) 1997-06-13 2005-03-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｓｍａｄ６及びその使用
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
US7399633B2 (en) 2000-10-27 2008-07-15 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
PT1456380E (pt) 2001-11-02 2012-07-23 Giuliani Int Ltd Inibidores smad7 para o tratamento de doenças do snc
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7575925B2 (en) 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20070036769A9 (en) 2004-06-03 2007-02-15 Linheng Li BMP pathway methods and compositions
SG177981A1 (en) 2005-05-18 2012-02-28 Array Biopharma Inc 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo COMMON USE OF A TGF BETA SIGNAL HEMMER AND AN ANTITUMORAL AGENT
EP3424507A1 (en) 2006-03-24 2019-01-09 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
BRPI0714409A2 (pt) 2006-07-14 2013-03-12 Novartis Ag derivados de pirimidina como inibidores de alk-5
CN103627671A (zh) 2007-01-30 2014-03-12 佐治亚大学研究基金会 产生中内胚层细胞及多能游走细胞的方法与细胞群及用途
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2009097140A1 (en) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
WO2009104825A1 (en) * 2008-02-18 2009-08-27 Kaist Method for inducing the defferentiation of embryonic stem cells into hemangioblast
EP2712921B1 (en) 2008-05-06 2018-07-11 Astellas Institute for Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
EP4585589A3 (en) 2008-12-03 2025-11-19 The Scripps Research Institute Stem cell cultures
US8993343B2 (en) 2009-01-28 2015-03-31 Korea Research Institute Of Bioscience And Biotechnology CD93 or use of soluble fragment thereof
EP2398897B1 (en) 2009-02-20 2017-06-28 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
KR101720961B1 (ko) * 2009-02-27 2017-03-29 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 다능성 세포의 분화
AU2010235161B2 (en) 2009-04-09 2015-01-22 Sangamo Therapeutics, Inc. Targeted integration into stem cells
AU2010306627B2 (en) 2009-10-16 2014-07-17 The Scripps Research Institute Induction of pluripotent cells
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
JPWO2011096482A1 (ja) * 2010-02-03 2013-06-13 国立大学法人 東京大学 多能性幹細胞を用いた免疫機能再建法
US9206394B2 (en) 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
JP5777115B2 (ja) * 2010-03-18 2015-09-09 国立大学法人京都大学 多能性幹細胞から中胚葉細胞への分化誘導法
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
JP5984217B2 (ja) * 2010-06-15 2016-09-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
CA2993567C (en) 2010-07-21 2022-06-28 Sangamo Biosciences, Inc. Methods and compositions for modification of a t-cell receptor gene
EP2601288B1 (en) 2010-08-05 2016-04-06 Wisconsin Alumni Research Foundation Simplified basic media for human pluripotent cell culture
EP2603227B1 (en) 2010-08-12 2017-10-04 Fate Therapeutics, Inc. Improved hematopoietic stem and progenitor cell therapy
US9181529B2 (en) * 2010-10-19 2015-11-10 Cellular Dynamics International, Inc. Titration of differentiation medium components
PE20141114A1 (es) 2010-12-20 2014-09-15 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
WO2012087965A2 (en) 2010-12-22 2012-06-28 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
PT2658965E (pt) 2010-12-31 2016-06-06 Universität Für Bodenkultur Wien Método para a generação de células induzidas e células diferenciadas
US8700106B2 (en) 2011-03-09 2014-04-15 Universal Electronics Inc. System and method for provision of infrared signalling in smart phone devices
CN102732483B (zh) 2011-03-31 2014-12-03 北京大学 造血祖细胞的制备方法及其专用培养基
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2013009825A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
WO2013025042A2 (ko) 2011-08-16 2013-02-21 사회복지법인 삼성생명공익재단 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물
CN102329769B (zh) 2011-09-28 2013-07-31 浙江大学 一种获得造血干细胞的方法
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
CN104053769A (zh) * 2011-11-21 2014-09-17 大学健康网络 造血祖细胞群体和富集其干细胞的方法
EP3785767A1 (en) 2011-12-02 2021-03-03 Fate Therapeutics, Inc. Enhanced stem cell composition
EP2788475A1 (en) 2011-12-05 2014-10-15 Primorigen Biosciences Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
CA2858069C (en) * 2011-12-08 2020-02-11 Novartis Ag Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
EP2606884A1 (en) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
RU2650811C2 (ru) 2012-02-24 2018-04-17 Фред Хатчинсон Кэнсер Рисерч Сентер Композиции и способы лечения гемоглобинопатии
US20150056225A1 (en) 2012-04-17 2015-02-26 University Of Washington Through Its Center For Commercialization HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof
WO2013158309A2 (en) 2012-04-18 2013-10-24 The Board Of Trustees Of The Leland Stanford Junior University Non-disruptive gene targeting
EP2841563B1 (en) * 2012-04-24 2019-06-12 Dan S. Kaufman Method for developing natural killer cells from stem cells
EP2853590B1 (en) 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
KR102437522B1 (ko) 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
US20150148292A1 (en) 2012-07-09 2015-05-28 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
SG11201503045YA (en) 2012-10-19 2015-05-28 Agency Science Tech & Res Methods of differentiating stem cells into one or more cell lineages
US9382531B2 (en) 2012-10-22 2016-07-05 Wisconsin Alumni Research Foundation Induction of hemogenic endothelium from pluripotent stem cells
WO2014089212A1 (en) 2012-12-05 2014-06-12 Sangamo Biosciences, Inc. Methods and compositions for regulation of metabolic disorders
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
JP6677631B2 (ja) * 2013-03-13 2020-04-08 ウイスコンシン アラムナイ リサーチ ファウンデーシヨンＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 定義された条件下におけるヒト多能性幹細胞の造血内皮分化のための方法及び材料
WO2015142314A1 (en) 2013-03-15 2015-09-24 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
AU2014248119B2 (en) 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
JP2016522679A (ja) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
US10117899B2 (en) 2013-10-17 2018-11-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
CN113699159A (zh) 2014-03-28 2021-11-26 明尼苏达大学评议会 涉及经工程改造的cd16的多肽、细胞和方法
EP3134515B1 (en) 2014-04-24 2019-03-27 Board of Regents, The University of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
CN103937743B (zh) 2014-04-27 2017-12-01 浙江大学 一种利用三维诱导系统获得造血干细胞的方法
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US20180112180A1 (en) 2015-01-26 2018-04-26 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
US20170020922A1 (en) 2015-07-16 2017-01-26 Batu Biologics Inc. Gene editing for immunological destruction of neoplasia
CN117070468A (zh) 2015-10-05 2023-11-17 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
JP6928604B2 (ja) 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2017164257A1 (ja) 2016-03-23 2017-09-28 国立大学法人京都大学 血球分化能の高い中胚葉誘導方法
US11377637B2 (en) 2016-04-15 2022-07-05 Memorial Sloan Kettering Cancer Center Transgenic T cell and chimeric antigen receptor T cell compositions and related methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Gori JL, et al. Efficient generation, purification, and expansion of CD34+ hematopoietic progenitor cells from nonhuman primate–induced pluripotent stem cells. Blood, Journal of American Society of Hematology. 2012 Sep 27;120(13):e35-44. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210062139A1 (en) * 2017-12-28 2021-03-04 Kaneka Corporation Cell aggregation suppressor
US20240043800A1 (en) * 2021-02-05 2024-02-08 Sungkwang Medical Foundation Method for differentiating pluripotent stem cell-derived hemogenic endothelial cells into lymphoid lineage cells

Also Published As

Publication number Publication date
JP2021058223A (ja) 2021-04-15
US20200248142A1 (en) 2020-08-06
HK1247245A1 (zh) 2018-09-21
US20260062676A1 (en) 2026-03-05
US10626372B1 (en) 2020-04-21
US20230212518A1 (en) 2023-07-06
AU2022203153A1 (en) 2022-06-02
JP2023058748A (ja) 2023-04-25
US12385012B2 (en) 2025-08-12
EP3250680A1 (en) 2017-12-06
US11634688B2 (en) 2023-04-25
WO2016123100A1 (en) 2016-08-04
JP7236476B2 (ja) 2023-03-09
JP2019103521A (ja) 2019-06-27
SG10202101358XA (en) 2021-03-30
AU2024287257A1 (en) 2025-01-23
JP6800859B2 (ja) 2020-12-16
CN107429230A (zh) 2017-12-01
AU2016211671A1 (en) 2017-08-10
SG11201706041XA (en) 2017-08-30
JP7720337B2 (ja) 2025-08-07
JP2025078772A (ja) 2025-05-20
US20180072992A1 (en) 2018-03-15
EP3250680A4 (en) 2018-12-05
JP2018502591A (ja) 2018-02-01
CN107429230B (zh) 2021-11-12
AU2022203153B2 (en) 2024-10-03
CN114058582A (zh) 2022-02-18
CA2974381A1 (en) 2016-08-04
JP6836803B2 (ja) 2021-03-03

Similar Documents

Publication Publication Date Title
AU2022203153B2 (en) Methods and compositions for inducing hematopoietic cell differentiation
AU2023203874B2 (en) Methods and compositions for inducing hematopoietic cell differentiation
CA2974381C (en) Methods and compositions for inducing hematopoietic cell differentiation
HK40061773A (en) Methods and compositions for inducing hematopoietic cell differentiation
HK1247245B (zh) 用於诱导造血细胞分化的方法和组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)